Your browser doesn't support javascript.
loading
Extracellular Matrix as a Driver of Chronic Lung Diseases.
Burgess, Janette K; Weiss, Daniel J; Westergren-Thorsson, Gunilla; Wigen, Jenny; Dean, Charlotte H; Mumby, Sharon; Bush, Andrew; Adcock, Ian M.
Affiliation
  • Burgess JK; Department of Pathology and Medical Biology.
  • Weiss DJ; Groningen Research Institute for Asthma and COPD, and.
  • Westergren-Thorsson G; W.J. Kolff Institute for Biomedical Engineering and Materials Science, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Wigen J; Department of Medicine, University of Vermont, Burlington, Vermont.
  • Dean CH; Lung Biology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.
  • Mumby S; Lung Biology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.
  • Bush A; National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
  • Adcock IM; National Heart and Lung Institute, Imperial College London, London, United Kingdom; and.
Am J Respir Cell Mol Biol ; 70(4): 239-246, 2024 Apr.
Article de En | MEDLINE | ID: mdl-38190723
ABSTRACT
The extracellular matrix (ECM) is not just a three-dimensional scaffold that provides stable support for all cells in the lungs, but also an important component of chronic fibrotic airway, vascular, and interstitial diseases. It is a bioactive entity that is dynamically modulated during tissue homeostasis and disease, that controls structural and immune cell functions and drug responses, and that can release fragments that have biological activity and that can be used to monitor disease activity. There is a growing recognition of the importance of considering ECM changes in chronic airway, vascular, and interstitial diseases, including 1) compositional changes, 2) structural and organizational changes, and 3) mechanical changes and how these affect disease pathogenesis. As altered ECM biology is an important component of many lung diseases, disease models must incorporate this factor to fully recapitulate disease-driver pathways and to study potential novel therapeutic interventions. Although novel models are evolving that capture some or all of the elements of the altered ECM microenvironment in lung diseases, opportunities exist to more fully understand cell-ECM interactions that will help devise future therapeutic targets to restore function in chronic lung diseases. In this perspective article, we review evolving knowledge about the ECM's role in homeostasis and disease in the lung.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies pulmonaires Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Am J Respir Cell Mol Biol Sujet du journal: BIOLOGIA MOLECULAR Année: 2024 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies pulmonaires Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Am J Respir Cell Mol Biol Sujet du journal: BIOLOGIA MOLECULAR Année: 2024 Type de document: Article